Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function.
ABCC1 and ABCG2 are ubiquitous ATP-binding cassette transmembrane proteins that play an important role in multidrug resistance (MDR). In this study, we evaluated the possible interaction of vandetanib, an orally administered drug inhibiting multiple receptor tyrosine kinases, with ABCC1 and ABCG2 in...
Main Authors: | Li-sheng Zheng, Fang Wang, Yu-hong Li, Xu Zhang, Li-ming Chen, Yong-ju Liang, Chun-ling Dai, Yan-yan Yan, Li-yang Tao, Yan-jun Mi, An-kui Yang, Kenneth Kin Wah To, Li-wu Fu |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2009-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2669214?pdf=render |
Similar Items
-
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
by: Siemann, D, et al.
Published: (2009) -
Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
by: Hari Deshpande, et al.
Published: (2011-01-01) -
Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
by: Jaclyn Flanigan, et al.
Published: (2010-08-01) -
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
by: Jeffrey A Meyerhardt, et al.
Published: (2012-01-01) -
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.
by: Carlomagno, F, et al.
Published: (2009)